News from our parent company, A.forall:
A.forall Group has signed a definitive agreement to sell its Retail & Hospital (R&H) business unit – also known as The Pharmacy House – to Abacus Medicine, a pharmaceutical company specializing in parallel distribution across Europe. The transaction is expected to close before year-end, subject to customary closing conditions.
At the same time, A.forall announces the appointment of Steen Vangsgaard as its new Group CEO. He succeeds Filip Van de Vliet, who has led the company since 2019 and will transition into the role of Chairman of the Board.
These changes are the result of a deliberate strategic decision: A.forall is focusing 100% on the development, licensing and commercialization of generic medicines worldwide.
With a sharper strategy and a clear direction, A.forall is ready for its next chapter — focused, ambitious and committed to generics.
